Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Cisplatin 101Radiotherapy 53Brachytherapy 41Paclitaxel 37Carboplatin 36Surveys and Questionnaires 28Blood Specimen Collection 20pembrolizumab 19Radiation 17Magnetic Resonance Spectroscopy 17Drug Therapy 17Colposcopy 16Bevacizumab 15Methods 14Early Intervention, Educational 12toripalimab 11Topotecan 11Radiotherapy, Intensity-Modulated 11Papanicolaou Test 11Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Chemoradiotherapy 11Biopsy 11camrelizumab 10Mass Screening 10Gemcitabine 10Patient Navigation 9Papillomavirus Vaccines 9Nivolumab 9Fluorodeoxyglucose F18 9Educational Status 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uterine Cervical Neoplasms × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡